Pharmacotherapy for stimulant-related disorders

Curr Psychiatry Rep. 2013 Nov;15(11):415. doi: 10.1007/s11920-013-0415-y.


Stimulant-related disorders (SRD) continue to be an important public health problem for which there are presently no approved pharmacotherapies. Although behavioral interventions provide some benefit response varies. The development of novel and effective pharmacotherapies continues to be a research priority. Understanding neural mechanisms critical to the action of stimulants has helped reveal several potential pharmacotherapies that have already shown promise in controlled clinical trials. Common to some of these medications is the ability to reverse neural deficits in individuals with SRD. Results from thoroughly conducted clinical trials continue to broaden our knowledge increasing the possibility of soon developing effective pharmacotherapies for SRD.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Central Nervous System Stimulants*
  • Clinical Trials as Topic
  • Humans
  • Narcotic Antagonists / therapeutic use*
  • Substance-Related Disorders / drug therapy*


  • Central Nervous System Stimulants
  • Narcotic Antagonists